Navigation Links
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results

-- Currently enrolling patients in U.S. Phase II clinical trial for cocaine

addiction -- Expect to initiate U.S. Phase II clinical trial for methamphetamine

addiction in second quarter of 2008

CORAL GABLES, Fla., March 26 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today reported financial results for the fourth quarter and year ended December 31, 2007.

Commenting on the year, Patrick J. McEnany, Chief Executive Officer of Catalyst Pharmaceutical Partners, noted, "Operationally, 2007 was an important year for Catalyst, during which time we achieved several key milestones. Most notably, we developed CPP-109, Catalyst's finished dosage form of vigabatrin, which is now being used in our first U.S. Phase II clinical trial. We also reported successful results of the use of vigabatrin to treat cocaine addiction, from a New York University, investigator-sponsored, double-blind, placebo-controlled Phase II trial in Mexico that was partially supported by Catalyst. That trial confirmed the positive results of the prior two Mexican human pilot studies."

Mr. McEnany continued, "In preparation for our clinical development efforts, we have also strengthened our management team with two key appointments. Steven R. Miller, Ph.D. joined the Company as Vice President of Pharmaceutical Development and Project Management and Patrick Kenny came on board as Director - Corporate Clinical Compliance."

"During 2007, we expanded our Scientific Advisory Board with two new members; Dr. Thomas Kosten, the Waggoner Professor of Psychiatry and Neuroscience at Baylor College of Medicine, and Dr. Richard Rawson of the University of California, Los Angeles' Department of Psychiatry. Drs. Kosten and Rawson are both key opinion leaders in the field of substance abuse and are contributing greatly to the achievement of Catalyst's goals."

"We are especially pleased that the positive results from our Mexico trial were discussed in Newsweek magazine's cover article on addiction in the March 3, 2008 issue. In the article, one of the foremost experts in the field of addiction noted that the results of this trial provide the best efficacy signal of any trial conducted so far for cocaine treatment and that treatment with vigabatrin seems especially promising, even for patients that are hardest to treat -- long-term cocaine addicts. We believe strongly in the viability of our technology and the promise that treatment with CPP-109 may bring to patients, the healthcare system and society at large."

Financial Results

For the year ended December 31, 2007, the Company's net loss was $4,139,493, or $0.33 per basic and diluted share, compared to a net loss of $2,729,454, or $0.36 per basic and diluted share, in the prior year. Results for 2007 and 2006 include non-cash charges relating to stock-based compensation of $556,343 and $1,220,739, respectively.

Research and development expenses for 2007 were $2,990,659, compared to $1,087,144 in 2006. This includes non-cash stock-based compensation for 2007 and 2006 of $365,107 and $344,649, respectively.

General and administrative expenses for 2007 were $2,036,470, compared to $1,815,183 in 2006. This includes non-cash stock-based compensation for 2007 and 2006 of $191,236 and $876,090, respectively.

For the fourth quarter of 2007, the Company's net loss was $944,938, or $0.08 per basic and diluted share, compared to a net loss of $741,241, or $0.07 per basic and diluted share, for the same period in 2006. Results for the fourth quarters of 2007 and 2006 include non-cash charges relating to stock-based compensation of $79,260 and $150,796, respectively.

As a development stage pharmaceutical company, Catalyst had no revenues during 2007 and 2006.

At December 31, 2007, the Company had cash and cash equivalents totaling $15.9 million and no long-term debt. The Company believes that its existing cash and cash equivalents will be sufficient to meet its projected operating requirements through the middle of 2009.

Company Development Update

In August 2007, Catalyst submitted to the U.S. Food & Drug Administration (FDA) the results of a bioequivalence study demonstrating that CPP-109 is bioavailable and bioequivalent to Sabril(R) Tablets, the version of vigabatrin marketed in Europe by Sanofi Aventis.

In December 2007, Catalyst announced positive initial top-line results from a Catalyst-supported, investigator-initiated, Phase II double-blind, placebo-controlled trial, in which vigabatrin met its primary efficacy endpoint of abstinence during the last weeks of treatment for cocaine addiction. Additional results of this trial will be reported when they become available. This 103-subject trial is the first randomized, double-blind, placebo-controlled clinical trial studying vigabatrin's effectiveness in treating cocaine addiction. These data show that a statistically significantly greater number of subjects treated with vigabatrin were able to abstain from cocaine usage during the last three weeks of the dosing period compared to those receiving placebo. Achievement of abstinence for an extended period during treatment is the critical first step for cocaine addicted patients to potentially achieve abstinence for much longer time periods. The data confirm the positive results seen in two previous open-label trials conducted in 2003 and 2004.

In January 2008, Catalyst announced that it has initiated enrollment of patients for its 180-patient, U.S. Phase II clinical trial evaluating the use of CPP-109 in treating patients with cocaine addiction. The Phase II trial is designed as a randomized, double-blind, placebo-controlled, intent-to-treat, multi-center trial to evaluate the safety and efficacy of CPP-109 as a treatment for cocaine addiction. Under the trial protocol, patients will be treated for a period of 12 weeks, with an additional 12 weeks of follow-up. The primary objective of the trial is to demonstrate that a larger proportion of CPP-109-treated subjects than placebo-treated subjects are cocaine-free during their last two weeks of treatment (weeks 11 and 12). Additionally, Catalyst will be measuring a number of secondary endpoints based on reductions of cocaine use and craving. Catalyst expects to initiate a similar trial in patients with methamphetamine addiction in the second quarter of 2008.

The Company expects to receive initial top-line results from its Phase II clinical trial for cocaine addiction in the fourth quarter of 2008. Top-line results of the trial for methamphetamine addiction are expected in the third quarter of 2009.

About Catalyst Pharmaceutical Partners, Inc.

Catalyst Pharmaceutical Partners is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for nine patents and four patents pending in the United States relating to the right to use vigabatrin to treat a wide variety of substance addictions. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending in more than 30 countries. The Company's initial product candidate is CPP-109, which is the Company's finished dosage form of vigabatrin, also referred to in the literature as gamma-vinyl-GABA or GVG. CPP-109 has been granted "Fast Track" status by the FDA for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs. For more information about the Company, go to

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties which may cause the Company's actual results in future periods to differ materially from forecasted results. A number of factors, including those described in the Annual Report on Form 10-K that the Company has filed with the U.S. Securities and Exchange Commission ("SEC") reporting its financial position and results of operations as of and for the year ended December 31, 2007, could adversely affect the Company's ability to obtain these results. Copies of the Company's filings with the SEC are available from the SEC or may be obtained upon request from the Company. The Company does not undertake any obligation to update the information contained herein, which speaks only as of this date.


(a development stage company)


Year Ended December 31,

2007 2006

Revenues $ - $ -

Operating costs and expenses:

Research and development 2,990,659 1,087,144

General and administrative 2,036,470 1,815,183

Total operating costs and expenses 5,027,129 2,902,327

Loss from operations (5,027,129) (2,902,327)

Interest income 887,636 172,873

Loss before income taxes (4,139,493) (2,729,454)

Provision for income taxes - -

Net loss $(4,139,493) $(2,729,454)

Net loss per share - basic and diluted $ (0.33) $ (0.36)

Weighted average shares outstanding

- basic and diluted 12,525,405 7,687,630


(a development stage company)


December 31,

2007 2006


Current assets:

Cash and cash equivalents $15,943,896 $20,434,702

Interest receivable 63,709 85,787

Prepaid expenses 524,081 67,333

Total current assets 16,531,686 20,587,822

Property and equipment, net 127,788 20,157

Deposits 20,448 11,500

Total assets $16,679,922 $20,619,479



Accounts payable $219,866 $448,072

Accrued expenses and other liabilities 83,419 324,774

Total current liabilities 303,285 772,846

Accrued expenses and other liabilities,

non current 53,880 -

Total liabilities 357,165 772,846

Total stockholders' equity 16,322,757 19,846,633

Total liabilities and stockholders' equity 16,679,922 20,619,479

SOURCE Catalyst Pharmaceutical Partners
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
(Date:9/1/2017)... N.J. , Sept. 1, 2017  Bayer will present ... the European Society for Medical Oncology (ESMO) 2017 Congress, September ... presented will include new preclinical and clinical data on Bayer,s ... two earlier pipeline projects. ... the best minds in cancer research at ESMO," said ...
(Date:8/29/2017)... -- ivWatch, LLC, the leading provider of continuous monitoring devices for ... awarded an Innovative Technology contract from Vizient, Inc., the largest member-driven ... ... early detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ivWatch based ...
(Date:8/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will present at the ... in New York . John Greisch ... present at 11:05 a.m. Eastern Time. The ... A recorded replay will be available one hour after the ... About Hill-Rom Holdings, Inc. ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... Each year Athletic Trainers from ... Trainers’ Association Annual Clinical Symposium and Expo. New research is revealed, evidence based ... Trainers are acknowledged by their peers with accolades and highly prestigious awards. This ...
(Date:9/20/2017)... ... 2017 , ... Medicare doesn’t have the authority to negotiate ... their prescription drugs, according to a new comparison of drug plans by ... there’s no consistency in drug pricing among drug plans,” states TSCL’s Medicare policy ...
(Date:9/20/2017)... ... 20, 2017 , ... “Finn Mouseson”: follows the exciting story of a mouse ... mouse sets out on a journey that will show that friends are to be ... newly published author and illustrator, Melody Gersonde-Mickelson, who has earned a bachelor’s degree in ...
(Date:9/20/2017)... ... ... “The Financial Favor of God; Second Edition”: a personal and exquisite recipe for ... of published author, Brooks Rathell. , “We typically hear about the favor of God. ... favor of God. Not only does it exist, but it is meant for you. ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, a ... leader, Denise Flannery, to its strategic advisory and client development team. , ... work with clients across different industries to develop and implement market-justified strategies, modernize ...
Breaking Medicine News(10 mins):